380 related articles for article (PubMed ID: 33989464)
1. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.
Zhdanava M; Pilon D; Ghelerter I; Chow W; Joshi K; Lefebvre P; Sheehan JJ
J Clin Psychiatry; 2021 Mar; 82(2):. PubMed ID: 33989464
[TBL] [Abstract][Full Text] [Related]
2. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of treatment-resistant depression among veterans in the United States.
Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
[TBL] [Abstract][Full Text] [Related]
4. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
[TBL] [Abstract][Full Text] [Related]
5. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
[No Abstract] [Full Text] [Related]
6. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
7. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
[TBL] [Abstract][Full Text] [Related]
8. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of Adults with Major Depressive Disorder in the United States (2019).
Greenberg P; Chitnis A; Louie D; Suthoff E; Chen SY; Maitland J; Gagnon-Sanschagrin P; Fournier AA; Kessler RC
Adv Ther; 2023 Oct; 40(10):4460-4479. PubMed ID: 37518849
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and economic burden of treatment-resistant depression in Thailand.
Prasartpornsirichoke J; Pityaratstian N; Poolvoralaks C; Sirinimnualkul N; Ormtavesub T; Hiranwattana N; Phonsit S; Rungnirundorn T
BMC Public Health; 2023 Aug; 23(1):1541. PubMed ID: 37573321
[TBL] [Abstract][Full Text] [Related]
11. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
[TBL] [Abstract][Full Text] [Related]
12. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
Olfson M; Amos TB; Benson C; McRae J; Marcus SC
J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
[TBL] [Abstract][Full Text] [Related]
13. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
[TBL] [Abstract][Full Text] [Related]
14. Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers.
Shrestha A; Roach M; Joshi K; Sheehan JJ; Goutam P; Everson K; Heerlein K; Jena AB
Psychiatr Serv; 2020 Jun; 71(6):593-601. PubMed ID: 32237982
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
[TBL] [Abstract][Full Text] [Related]
16. Economic implications of treatment-resistant depression among employees.
Greenberg P; Corey-Lisle PK; Birnbaum H; Marynchenko M; Claxton A
Pharmacoeconomics; 2004; 22(6):363-73. PubMed ID: 15099122
[TBL] [Abstract][Full Text] [Related]
17. The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria.
Walter E; Traunfellner M; Gleitsmann M; Zalesak M; Helmenstein C
J Med Econ; 2023; 26(1):1432-1444. PubMed ID: 37768864
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
[TBL] [Abstract][Full Text] [Related]
19. Treatment-resistant depression and major depression with suicide risk-The cost of illness and burden of disease.
Sousa RD; Gouveia M; Nunes da Silva C; Rodrigues AM; Cardoso G; Antunes AF; Canhao H; de Almeida JMC
Front Public Health; 2022; 10():898491. PubMed ID: 36033799
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
